FDA Approves Durvalumab for Muscle Invasive Bladder Cancer By Ogkologos - May 2, 2025 524 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to... August 14, 2025 ¿Comer alimentos a la parrilla o asados puede provocar cáncer? September 14, 2023 Breastfeeding Duration Could Influence Breast Cancer Risk, Study Shows September 27, 2019 EMA Pharmacovigilance Risk Assessment Committee Advice on Safety-Related Aspects of the... February 19, 2021 Load more HOT NEWS What Do “Health Equity” and “Quality Care” Mean in Cancer Care? Teacher on Leave for Breast Cancer Treatment Forced to Pay for... WHO’s plans to create a ‘cervical cancer-free future’ Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of...
